BiotechTube
StrideBio

StrideBio

Durham, United States· Est.
stridebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $166.5M

Overview

StrideBio, founded in 2015 and based in Durham, NC, is a private, pre-revenue biotech focused on advancing gene therapy through its novel AAV engineering platform. The company's STRIVE platform utilizes structure-inspired design to create capsids with improved tropism, reduced pre-existing immunity, and enhanced manufacturability compared to natural AAV serotypes. Its lead programs target genetic conditions like Friedreich's ataxia and a severe pediatric epilepsy (SLC13A5 deficiency), with a broader pipeline in discovery and preclinical stages. StrideBio has secured significant venture funding and established key partnerships with Takeda and Arbor Biotechnologies to validate and expand its platform's reach.

NeurologyCardiovascularMetabolicGenetic Disorders

Technology Platform

STRIVE™ (Structure-inspired AAV Vector Engineering) platform for rational design of novel AAV capsids with improved tissue targeting, reduced immunogenicity, and enhanced manufacturability.

Funding History

3
Total raised:$166.5M
Series B$80M
Series A$81.5M
Seed$5M

Opportunities

The STRIVE platform's ability to solve key AAV limitations (immunogenicity, tropism) opens large market opportunities in both rare and more prevalent genetic diseases.
Strategic partnerships with major pharma like Takeda provide validation, non-dilutive funding, and a path to expand the platform's reach into new therapeutic areas.
The growing gene therapy market and premium pricing for transformative one-time treatments create a favorable commercial environment for successful programs.

Risk Factors

Clinical failure of lead program STRX-110 or unexpected toxicity from novel engineered capsids would significantly devalue the platform.
Intense competition in AAV engineering from well-funded rivals poses a threat to market positioning.
High manufacturing costs and evolving regulatory/reimbursement hurdles for gene therapies present commercial execution risks.

Competitive Landscape

StrideBio competes in the crowded field of next-generation AAV vector engineering. Key competitors include public companies like 4D Molecular Therapeutics (4DMT) and privately-held firms like Dyno Therapeutics (partnered with Roche, Novartis), which also use computational and AI-driven approaches to design capsids. Traditional gene therapy companies (e.g., Spark/Pfizer, Novartis, Sarepta) using natural AAV serotypes represent both competitors and potential partners/customers for StrideBio's technology.

More companies in Cell & Gene Therapy →More companies in United States →